HE4 (Human Epididymis Protein-4)

HE4 (Human Epididymis Protein-4) is a specialized diagnostic tumor marker test designed to measure the concentration of Human Epididymis Protein-4 in the blood. HE4 is a biomarker whose expression is significantly elevated in epithelial ovarian cancer and certain other malignancies. Measuring HE4 levels is essential for monitoring disease recurrence or progression in patients diagnosed with ovarian cancer, as well as evaluating pelvic masses in conjunction with CA-125 and the Risk of Ovarian Malignancy Algorithm (ROMA).

Measurement of serum HE4 provides direct clinical insight into epithelial ovarian malignancy and tumor activity. Because early detection of recurrence and precise risk stratification support timely oncological intervention, specialized biochemical testing supplies essential clinical data for oncology, gynecology, gynecologic oncology, and internal medicine evaluations.

The test requires a blood specimen collected by a qualified person using standard serum separator containers under appropriate clinical conditions, followed by precise analysis using automated laboratory immunoassay techniques. Results must always be interpreted in conjunction with the patient's clinical presentation, imaging studies, menopausal status, and concurrent CA-125 levels.

Benefits of HE4 (Human Epididymis Protein-4) Testing

• Provides a precise quantitative measurement of serum HE4 tumor marker levels.
• Helps monitor recurrence and treatment response in epithelial ovarian cancer patients.
• Assists clinicians in evaluating pelvic masses and assessing malignancy risk (ROMA score).
• Aids in differentiating ovarian cancer from benign pelvic conditions.
• Supports tracking of specialized oncological and gynecological care plans.
• Complements CA-125 assays, pelvic ultrasound scans, and transvaginal imaging.
• Utilizes precise laboratory immunoassay techniques for reliable quantitative results.
• Assists specialists in determining appropriate surgical or therapeutic management strategies.
• Provides dependable turnaround times to support specialized clinical care.
• Utilizes standard venous blood collection procedures under medical supervision.

Clinical Indications and Applications

Oncological Monitoring: The primary clinical indication is monitoring disease progression, recurrence, or therapeutic response in patients diagnosed with epithelial ovarian cancer.

Clinical Assessment: The test is also utilized when evaluating women presenting with a pelvic mass to help assess the likelihood of malignancy, particularly when combined with CA-125.

Why Doctors Recommend This Test

Gynecologic oncologists, oncologists, gynecologists, and internal medicine specialists recommend this test when managing ovarian cancer patients or investigating complex pelvic masses. It delivers essential quantitative data required to guide safe clinical intervention.

Following proper blood collection guidelines will ensure a smooth and efficient testing procedure.

What Happens During The Procedure?

The collection procedure involves obtaining a blood specimen drawn from a vein by a qualified phlebotomist using a clean, standard collection container provided by the healthcare facility under appropriate supervision protocols.

Once obtained, the sample is tested in the laboratory using advanced immunoassay analyzers to quantify HE4 concentrations. The procedure takes only a few minutes.

Normal Reporting Time

The report for the HE4 (Human Epididymis Protein-4) test is generally available within 24 to 48 hours due to standard laboratory processing times. Results must be reviewed promptly with the referring oncologist or specialist.

Who Should Consider This Test?

• Patients diagnosed with epithelial ovarian cancer monitored for recurrence or treatment efficacy.
• Women evaluated for pelvic masses or high-risk ovarian conditions as directed by a clinician.

Understanding Test Results

Test results provide quantitative concentrations of serum HE4, evaluated against established laboratory reference ranges and menopausal status.

Normal Findings: Normal or low HE4 levels indicate a lower likelihood of active epithelial ovarian malignancy.

Abnormal Findings: Elevated HE4 levels suggest the presence of epithelial ovarian cancer or disease recurrence, requiring comprehensive oncological evaluation and management.

Clinical Limitations

HE4 levels can be influenced by renal function and benign conditions to a lesser extent than CA-125, but results must always be interpreted alongside clinical history and imaging findings.

Important Safety Information

Severe pelvic pain, rapid abdominal swelling, or acute systemic symptoms require immediate medical attention. Patients must consult their healthcare provider or specialist to interpret tumor marker findings.